The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2016 EBA EU-wide stress test results

1 Aug 2016 07:07

RNS Number : 7910F
Royal Bank of Scotland Group PLC
01 August 2016
 

The Royal Bank of Scotland Group plc

 

Statement on the publication of the 2016 EBA EU-wide stress test results

 

01 August 2016

 

The Royal Bank of Scotland Group plc ("RBS") notes the announcement made today by the European Banking Authority ("EBA") and the Prudential Regulation Authority ("PRA") regarding the results of the 2016 EBA EU-wide stress test.

 

The 2016 EBA EU-wide stress test does not contain a pass/fail threshold.

 

On a fully loaded Basel 3 basis, RBS's modelled Common Equity Tier 1 ("CET1") ratio under the adverse scenario was 8.1% as at 31 December 2018. The low point CET1 ratio under this scenario was 7.8% as at 31 December 2017.

 

RBS's modelled leverage ratio under the adverse scenario was 3.6% on a fully loaded Basel 3 basis and 4.2% under the PRA transitional definition for leverage ratio as at 31 December 2018. The low point leverage ratio under this scenario was 3.5% on a fully loaded Basel 3 basis as at 31 December 2016 and 4.2% under the PRA transitional definition as at 31 December 2017.

 

The cumulative impacts on modelled operating profit, impairments in the banking book and losses in the trading book under the adverse scenario over the three years to 31 December 2018 are shown in the table below.

 

Table 1 - EBA CET1 ratio stress test result under the Adverse scenario

 

Fully loaded

Basel 3

31 December 2015 published CET1 ratio

15.5%

(GBPm)

3-year cumulative net interest income

25,331

3-year cumulative gains on financial assets and liabilities held for trading or designated at fair value through profit and loss, net

1,197

3-year cumulative impairments on financial assets not measured at fair value through profit or loss

(7,916)

3-year cumulative profit / (loss) for the year(1)

(11,151)

CET1 capital

23,577

EBA calculated risk-weighted assets

291,624

Resulting EBA-calculated CET1 ratio in 2018

8.1%

(1) Including stressed conduct and litigation losses.

 

 

 

 

 

 

 

 

Table 2 - EBA leverage ratio stress test result under the adverse scenario

 

Fully loaded

Basel 3 basis

31 December 2015 published leverage ratio

5.6%

(GBPm)

Tier 1 capital

29,415

Total leverage ratio exposures

702,462

Resulting EBA-calculated leverage ratio in 2018

3.6%

Note: The EBA stress test results are based on hypothetical adverse and baseline macroeconomic scenarios and a common methodology developed by the EBA (including a static balance sheet) applied across all participating banks. Neither the baseline scenario nor the adverse scenario should in any way be construed as an RBS forecast or directly compared to other information prepared by RBS.

 

The EBA stress test results cannot be used to infer outcomes of the 2016 Bank of England ("BoE") stress tests for UK banks. There are key distinctions between the two regulatory stress tests, including a static balance sheet assumption for the EBA exercise therefore a number of initiatives such as balance sheet reduction (including asset sales and divestments), business growth and cost savings are not factored into the stress outcomes.

 

The EBA stress tests, like those run by the BoE, currently include substantial stressed conduct and litigation charges in the adverse scenario only, primarily in relation to US RMBS.

 

Commenting on the results, Ewen Stevenson, Chief Financial Officer, said:

 

"The EBA stress test results demonstrate our continued progress towards transforming the balance sheet to being safe and sustainable. Over recent years we have materially strengthened our CET1 ratio, substantially reduced our balance sheet and leverage, and continued to de-risk our asset exposures.

 

We are confident that in delivering our strategy, we will transform RBS into a low risk, resilient bank."

 

RBS will announce its 2016 Interim Results on Friday, 5th August 2016.

 

The detailed results of the stress test, as well as information on RBS exposures to central, regional and local governments in the European Economic Area, are available via the link below:

 

http://www.eba.europa.eu/risk-analysis-and-data/eu-wide-stress-testing/2016/results

 

For further information, please contact:

 

Investor Relations

Richard O'Connor

Head of Investor Relations

+44 (0) 20 7672 1758

 

RBS Media Relations

+44 (0) 131 523 4205

 

 

Forward Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to RBS and its subsidiaries' regulatory capital position, risk-weighted assets, impairment losses and credit exposures under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements typically containing words such as "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. These statements concern or may affect future matters, such as RBS's future economic results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, legislative, fiscal and regulatory developments, competitive conditions, technological developments, exchange rate fluctuations and general economic conditions. These and other factors, risks and uncertainties that may impact any forward-looking statement or RBS's actual results are discussed in RBS's UK Annual Report and materials filed with, or furnished to, the US Securities and Exchange Commission, including, but not limited to, RBS's Reports on Form 6-K and most recent Annual Report on Form 20-F. The forward-looking statements contained in this announcement speak only as of the date of this announcement and RBS does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFEETTILIIR
Date   Source Headline
17th Apr 201911:20 amRNSSegmental Reporting Restatement Document
1st Apr 20194:30 pmRNSDirector/PDMR Shareholding
29th Mar 20195:04 pmRNSTotal Voting Rights
27th Mar 20192:05 pmRNSPublication of Final Terms
20th Mar 201910:17 amRNSRBSG pricing of US$2 billion of Senior Notes
19th Mar 20198:30 amRNSMorgan Stanley European Financials Conference
13th Mar 20196:26 pmRNSNotice of Redemption
11th Mar 20193:00 pmRNSDirector/PDMR Shareholding
7th Mar 20194:56 pmRNSForm 8.3 - Findel plc
6th Mar 20192:45 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 20191:10 pmRNSForm 8.3 - MedicX Fund Limited
1st Mar 201912:01 pmRNSDirector/PDMR Shareholding
1st Mar 20197:00 amRNSFiling of Annual Report on Form 20-F with US SEC
28th Feb 20192:25 pmRNSDividend Declaration
28th Feb 201912:40 pmRNSTotal Voting Rights
26th Feb 20195:50 pmRNSPublication of Supplementary Prospectus
22nd Feb 201912:51 pmRNSUpdate on NatWest Markets transfer scheme
22nd Feb 201912:00 pmRNSDirector/PDMR Shareholding
15th Feb 20193:00 pmRNSPublication of Supplementary Prospectus
15th Feb 20197:02 amRNSDirectorate Change
15th Feb 20197:01 amRNSAnnual Financial Report
15th Feb 20197:00 amRNSFinal Results
6th Feb 20194:16 pmRNSResult of Meeting
6th Feb 20192:55 pmRNSGM Statement
31st Jan 201911:42 amRNSTotal Voting Rights
29th Jan 20192:55 pmRNSDirector/PDMR Shareholding
25th Jan 20191:27 pmRNSForm 8.3 Disclosure
17th Jan 20194:10 pmRNSNotice of GM
9th Jan 20195:02 pmRNSHolding(s) in Company
31st Dec 20181:13 pmRNSTotal Voting Rights
28th Dec 20184:28 pmRNSDirector/PDMR Shareholding
27th Dec 20184:55 pmRNSDividend Declaration
18th Dec 20183:55 pmRNSDirectorate Change
14th Dec 20186:15 pmRNSRBS welcome credit ratings action by Fitch Ratings
14th Dec 20183:33 pmRNSPublication of a Prospectus
6th Dec 20184:40 pmRNSSecond Price Monitoring Extn
6th Dec 20184:35 pmRNSPrice Monitoring Extension
6th Dec 20182:16 pmRNSNatWest Markets transfer scheme
30th Nov 20182:30 pmRNSTotal Voting Rights
30th Nov 20181:12 pmRNSDirector/PDMR Shareholding
29th Nov 20184:28 pmRNSDividend Declaration
29th Nov 20184:07 pmRNSNotice of Redemption
29th Nov 201811:34 amRNSNotice of Rdemption
29th Nov 201811:33 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 201811:31 amRNSNotice of Redemption
29th Nov 20188:00 amRNSRBS Investor Seminar: Commercial Banking
28th Nov 20185:09 pmRNS2018 Bank of England stress test results
16th Nov 201812:00 pmRNSDirector/PDMR Shareholding
9th Nov 20184:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.